Application
CLDN7 Antibody (C-term) western blot analysis in Hela cell line lysates (35ug/lane).This demonstrates the CLDN7 antibody detected the CLDN7 protein (arrow).Application
CLDN7 antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human prostate carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the CLDN7 antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.Application
CLDN7 Antibody (C-term) flow cytometric analysis of Hela cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Product Name | CLDN7 Antibody (C-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | CLDN7; CEPTRL2; CPETRL2; Claudin-7 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBIHCFC |
| WB:1:100~500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | CEPTRL2 CPETRL2 |
|---|---|
| Alternative Names | CLDN7 CEPTRL2 CPETRL2 Claudin-7 |
| Molecular Weight(MW) | 22418 Da |
| Function | Plays a major role in tight junction-specific obliteration of the intercellular space (By similarity) |
| Tissue Specificity | Expressed in kidney, lung and prostate. Isoform 1 seems to be predominant, except in some normal prostate samples, where isoform 2 is the major form. Down-regulated in breast cancers, including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) (at protein level), as well as in several cancer cell lines. Loss of expression correlates with histological grade, occurring predominantly in high-grade lesions |
| Cellular Localization | Cell membrane; Multi-pass membrane protein. Lateral cell membrane. Cell junction, tight junction. Note=Co- localizes with EPCAM at the lateral cell membrane and tight junction |
| Entrez Gene | 1366 |
|---|---|
| Nucleotide Accession | NP_001171951.1 NP_001298.3 |
Application
CLDN7 Antibody (C-term) western blot analysis in Hela cell line lysates (35ug/lane).This demonstrates the CLDN7 antibody detected the CLDN7 protein (arrow).
Application
CLDN7 antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human prostate carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the CLDN7 antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.
Application
CLDN7 Antibody (C-term) flow cytometric analysis of Hela cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Application Notes | WB:1:100~500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
